Patents Examined by Charanjit Aulakh
  • Patent number: 11179387
    Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: November 23, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • Patent number: 11180503
    Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 23, 2021
    Assignee: ELI LILLY AND COMPANY
    Inventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
  • Patent number: 11179383
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: November 23, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11174256
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: November 16, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao
  • Patent number: 11174229
    Abstract: Disclosed are d-amphetamine compounds and compositions comprising at least one organic acid covalently bound to d-amphetamine, having the structure of a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: November 16, 2021
    Assignee: KemPharm, Inc.
    Inventors: Sven Guenther, Guochen Chi, Travis Mickle
  • Patent number: 11174228
    Abstract: Disclosed are small molecule antagonists of ?4?7 integrin, and methods of using them to treat a number of specific diseases or conditions.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: November 16, 2021
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Matthew G. Bursavich, Dawn M. Troast, Bryce A. Harrison, Blaise S. Lippa, Bruce N. Rogers, Kyle D. Konze, Aleksey I. Gerasyuto, Tyler Day, Fu-Yang Lin, Kristopher N. Hahn, Mats A. Svensson, Byungchan Kim, Cheng Zhong, Alexey A. Lugovskoy, Brian Sosa
  • Patent number: 11168079
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph E. Carpenter, Matthias Broekema, Jianxin Feng, Chunjian Liu, Wei Wang, Ying Wang
  • Patent number: 11161830
    Abstract: An object of the present invention is to provide a compound or a salt thereof having anti-HBV activity, a pharmaceutical composition, an anti-hepatitis B virus agent, a production inhibitor of DNA of a hepatitis B virus, and a production or secretion inhibitor of a hepatitis B surface antigen. According to the present invention, provided are a compound represented by General Formula [1] or a salt thereof: (in the formula, R1 represents a benzothiazolyl group which may be substituted (in which a carbon atom constituting the 6-membered ring of the benzothiazolyl group of R1 is bonded to the nitrogen atom of the pyridone ring); R2 represents a C2-6 alkenyl group which may be substituted, or the like; and R3 represents a hydrogen atom or the like).
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: November 2, 2021
    Assignee: FUJIFILM Corporation
    Inventors: Megumi Ookubo, Shinichiro Sekine, Tomoyuki Mashiko, Hyoei Kawai, Hirofumi Fukunaga
  • Patent number: 11155549
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: October 26, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long
  • Patent number: 11155548
    Abstract: A method of recovering a highly pure hydrocodone base from an impure hydrocodone preparation includes contacting the impure hydrocodone preparation with a weak acid in water to form a solution and adding a strong base to the solution in an amount sufficient to precipitate the pure hydrocodone base product. A highly pure hydrocodone base comprises less than 0.0025 wt % codeinone.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: October 26, 2021
    Assignee: NORAMCO, LLC
    Inventors: Jessica Cardot, Joshua Sasine, Paul Nichols
  • Patent number: 11147803
    Abstract: There is provided a therapeutic agent for Alzheimer's disease for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (I): or a pharmaceutically acceptable salt thereof, and memantine represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 19, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • Patent number: 11145830
    Abstract: Tridentate platinum, palladium, and gold complexes of Formulas A-I and A-II and tridentate iridium and rhodium compounds of Formulas B-I, B-II, and B-III suitable for delayed fluorescent and phosphorescent or phosphorescent emitters in display and lighting applications.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: October 12, 2021
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Guijie Li
  • Patent number: 11135231
    Abstract: Methods and compositions for preventing and/or treating diseases and conditions caused by certain apicomplexan infections are provided. The methods involve administering/providing to a subject one or more of tartrolon D and E, including isomers thereof. Exemplary apicomplexan infections that are prevented/treated by the compounds of the invention include those caused by Cryptosporidium, Babesia, Cyclospora, Isospora, Plasmodium, Sarcocystis, Besnoitia, Hammondia, Neospora, Theileria and Toxoplasma.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: October 5, 2021
    Assignees: Washington State University, Tufts Medical Center, Inc., University of Utah
    Inventors: Roberta O'Connor, Eric W. Schmidt
  • Patent number: 11136321
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: October 5, 2021
    Assignee: Aligos Therapeutics, Inc.
    Inventor: Sandrine Vendeville
  • Patent number: 11136331
    Abstract: There is provided a novel process for the preparation of a compound of formula I, wherein R1, R2, W, Z and are as described in the description, by demethylation of a corresponding O-methyl derivative with a borohydride-based reagent. This process may be used in the preparation of buprenorphine.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 5, 2021
    Assignee: CAMBREX CHARLES CITY, INC.
    Inventors: Par Holmberg, Lars Eklund, David Adams, Michael Letourneau, Margus Eek, Alo Soone
  • Patent number: 11136295
    Abstract: Disclosed are d-amphetamine compounds and compositions comprising at least one organic acid covalently bound to d-amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: October 5, 2021
    Assignee: KEMPHARM, INC.
    Inventors: Sven Guenther, Guochen Chi, Travis Mickle
  • Patent number: 11129820
    Abstract: The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: September 28, 2021
    Assignee: Vifor (International) AG
    Inventors: Collin D. Morris, Fritz Blatter, Giuseppe Lapadula, Stefan Reim, Michael Burgert, Erik Philipp
  • Patent number: 11130750
    Abstract: The present disclosure describes carbamate analogs of mibefradil, as well as their compositions and methods of use. The compounds block the activity of one or more isoforms of voltage-gated calcium channels and are useful in the treatment of diseases including, e.g., cancer.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: September 28, 2021
    Assignee: CAVION, INC.
    Inventors: Thomas E. Richardson, Michelle Higgin, Timothy MacDonald
  • Patent number: 11123341
    Abstract: A method of treating opioid use disorder involves administering a selective butyrylcholinesterase (BChE) inhibitor.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: September 21, 2021
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng
  • Patent number: 11116760
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: September 14, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Julian A. Codelli, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole Nava, Leena Patel, Stephane Perreault, Jason K. Perry, Kassandra F. Sedillo, Natalie Seeger, Kirk L. Stevens, Jennifer Anne Treiberg, Suet C. Yeung, Zhongdong Zhao